- Report
- January 2023
- 124 Pages
From €3090EUR$3,450USD£2,634GBP
- Report
- January 2023
- 134 Pages
Africa, Middle East
From €3090EUR$3,450USD£2,634GBP
- Report
- January 2023
- 160 Pages
Asia Pacific
From €3090EUR$3,450USD£2,634GBP
- Report
- January 2023
- 146 Pages
North America
From €3090EUR$3,450USD£2,634GBP
- Report
- January 2023
- 153 Pages
Europe
From €3090EUR$3,450USD£2,634GBP
- Report
- October 2022
- 209 Pages
Global
From €3986EUR$4,450USD£3,398GBP
- Report
- June 2024
- 200 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Report
- May 2024
- 140 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Report
- August 2022
- 120 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- January 2022
- 115 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- December 2021
- 130 Pages
Global
From €13431EUR$14,995USD£11,449GBP
- Report
- September 2021
- 49 Pages
Global
From €3578EUR$3,995USD£3,050GBP
- Report
- October 2024
- 96 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- July 2022
- 128 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Report
- June 2023
- 132 Pages
Global
From €851EUR$950USD£725GBP
The Bladder Drug market is a subset of the Urological Disorders Drugs market, which focuses on treatments for conditions related to the urinary tract. These drugs are used to treat a variety of conditions, including urinary incontinence, overactive bladder, bladder cancer, and urinary tract infections. Bladder drugs are typically administered orally, topically, or through injections. Commonly prescribed bladder drugs include anticholinergics, antispasmodics, and alpha-blockers.
The Bladder Drug market is highly competitive, with a range of generic and branded products available. Companies in the market include Astellas Pharma, Allergan, Pfizer, Merck, and Sanofi. Show Less Read more
